ContractReinstatement and Fourth • May 2nd, 2024 • Evofem Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledMay 2nd, 2024 Company IndustryTHIS REINSTATEMENT AND FOURTH AMENDMENT TO MERGER AGREEMENT AND WAIVER AGREEMENT, dated as of May 2, 2024 (this “Reinstatement and Amendment”), to that certain Agreement and Plan of Merger dated as of December 11, 2023 (as amended hereby and by that First Amendment dated January 8, 2024, that Second Amendment dated January 30, 2024, and that Third Amendment dated February 29, 2024, the “Merger Agreement”), is entered into by and among Aditxt, Inc., a Delaware corporation (“Parent”), Adifem, Inc., f/k/a Adicure, Inc., a Delaware corporation (“Merger Sub”) and Evofem Biosciences, Inc., a Delaware corporation (the “Company”, and, together with Parent and Merger Sub, the “Parties” and each, a “Party”). All defined terms used herein that are not otherwise defined herein shall have the meanings set forth in the Merger Agreement.